ReviewScientifica2025
Clinical Detection and Management of Colorectal Cancer Concerning the Gut Microbiome.
Review in Scientifica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut microbiota signatures and machine learning-based candidate feature prioritization in advanced colorectal cancer.Archives of microbiology · 2026Article
- Insights into the Relevance of the Interaction between Colorectal Cancer and Gut Microbiota-Derived Metabolites.Journal of cancer prevention · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a prevalent malignancy worldwide and a leading cause of cancer-related mortality, influenced by both genetic predisposition and environmental factors. Gut dysbiosis, characterized by an imbalance in the gut microbiome, has been identified as a significant contributor to CRC progression. Although considerable progress has been made in understanding the relationship between the gut microbiome and CRC, the precise underlying mechanisms remain incompletely elucidated. Recent studies emphasize the role of gut microorganisms in inducing DNA damage, promoting inflammation, and contributing to drug resistance, positioning the microbiome as a promising target for CRC prevention and therapy. This review examines the intricate relationship between gut microbiota and CRC, with a focus on tumorigenesis mechanisms and the potential utility of specific bacterial species as clinical biomarkers. Dysbiosis, often driven by dietary and environmental factors, has been implicated in CRC pathogenesis, with bacterial virulence factors, inflammatory pathways, and microbial metabolites playing central roles in disease progression. Strategies for modulating the gut microbiome, such as probiotic supplementation and other microbiome-targeted interventions, represent emerging therapeutic approaches. Additionally, this review discusses the challenges associated with translating microbiome research into clinical practice and proposes potential solutions. By advancing the understanding of microbiota-CRC interactions, this research offers valuable insights into novel strategies for CRC prevention, early detection, and treatment. Future studies aim to refine microbiome-based interventions, ultimately improving the clinical management of CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.